Checked
Leukemia Clinical Trials in Oklahoma
Open studies with at least one site in the state
Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.
- Open studies
- 28
- With a site in Oklahoma
- Most studies in
- Oklahoma City
- 23 of the studies shown
Studies
28 of 28, recruiting studies first. Cities are where the study lists a Oklahoma site.
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3NCT04269902· National Cancer Institute (NCI)
Oklahoma City
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554393· National Cancer Institute (NCI)
Oklahoma City
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554406· National Cancer Institute (NCI)
Oklahoma City
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2NCT05564390· National Cancer Institute (NCI)
Oklahoma City
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06317649· National Cancer Institute (NCI)
Oklahoma City
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06672146· National Cancer Institute (NCI)
Oklahoma City
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2NCT06317662· National Cancer Institute (NCI)
Oklahoma City
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT07437950· National Cancer Institute (NCI)
Oklahoma City
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group StudiesRecruitingNCT00736749· Children's Oncology Group
Oklahoma City, Tulsa
- Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRecruitingNCT07143669· Blueprint Medicines Corporation
Oklahoma City
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069· Alliance for Clinical Trials in Oncology
Oklahoma City
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingPhase 3NCT07321652· Alliance for Clinical Trials in Oncology
Oklahoma City
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3NCT04293562· Children's Oncology Group
Oklahoma City
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3NCT03959085· Children's Oncology Group
Oklahoma City, Tulsa
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyRecruitingPhase 1, Phase 2NCT04726241· PedAL BCU, LLC
Oklahoma City
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingPhase 1NCT05886049· National Cancer Institute (NCI)
Oklahoma City
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1NCT06001788· Kura Oncology, Inc.
Oklahoma City
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven TreatmentRecruitingNCT06274788· Fresenius Kabi
Oklahoma City
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2NCT06390319· St. Jude Children's Research Hospital
Tulsa
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingPhase 2NCT06533748· St. Jude Children's Research Hospital
Tulsa
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 4NCT06289673· St. Jude Children's Research Hospital
Tulsa
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)RecruitingNCT01351545· Center for International Blood and Marrow Transplant Research
Oklahoma City
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentRecruitingNCT01790152· Children's Oncology Group
Oklahoma City
- Pilot Imaging Study of LeukemiaRecruitingPhase 1NCT03633955· University of Oklahoma
Oklahoma City
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 3NCT06428019· AbbVie
Tulsa
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingPhase 1NCT05735184· Kura Oncology, Inc.
Oklahoma City
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774· Massive Bio, Inc.
Tulsa
- Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureRecruitingPhase 2NCT04905810· Brian Jonas
Oklahoma City
Other cancer studies in Oklahoma
Frequently asked questions
- Are there leukemia clinical trials in Oklahoma?
- Yes. 28 leukemia studies on ClinicalTrials.gov list at least one site in Oklahoma and are recruiting, about to recruit or enrolling by invitation, including sites in Oklahoma City, Tulsa.
- What does recruiting mean?
- Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
- How do I join a clinical trial?
- Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.
Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026